The first clever thing Center for Vein Restoration did was take sore legs seriously. A patient might arrive talking about a ropey vein, an ankle that swells after work, or a patch of skin that will not heal. For years, those complaints could be waved away as cosmetic, inevitable, or simply annoying. CVR built a company around a different reading: the surface clue can point to a circulation problem underneath, and that problem deserves a specialist.
That distinction turned out to be large enough to build on. Cardiovascular and thoracic surgeon Sanjiv Lakhanpal founded the Greenbelt, Maryland-based practice in 2007 after seeing the pain, disability, skin changes, and ulcers associated with undiagnosed or untreated chronic venous insufficiency. The company now says it operates more than 130 clinics across 23 states with more than 100 vein doctors. It reports 98 percent patient satisfaction and more than 700,000 patient interactions a year.
CVR is not a hospital and it is not a beauty chain wearing a lab coat. It is a physician-led network of office-based vascular clinics. Its customers are people with varicose or spider veins, but also people dealing with aching, heaviness, restless legs, swelling, skin discoloration, venous ulcers, and other effects of poor venous return. Referring primary-care doctors are another customer group, as are independent vein practices looking for a larger operational home.
The product is a care pathway
A typical journey starts with a consultation and duplex ultrasound. The imaging lets a clinician see how blood is moving and where valves are allowing reflux. From there, the physician can choose from a wide menu: radiofrequency or laser ablation, adhesive closure with VenaSeal, microfoam treatment with Varithena, mechanochemical ablation with ClariVein, ultrasound-guided sclerotherapy, or ambulatory phlebectomy for veins close to the surface.
The common logic is almost counterintuitive: close the malfunctioning vein. Blood does not lose its way. It reroutes through healthier vessels while the treated vein is gradually absorbed. Most procedures use local anesthetic, take an hour or less, and allow patients to go home the same day. ClariVein can take less than 30 minutes. VenaSeal avoids heat and multiple anesthetic injections. Phlebectomy uses tiny punctures rather than a large incision.
This is where the category changed. Older vein stripping could mean general anesthesia, hospitalization, larger incisions, and weeks away from normal life. Catheter-based techniques made care lighter and faster. CVR's contribution was to wrap those techniques in a repeatable delivery machine: imaging, credentialed doctors, benefit verification, scheduling, standardized support, and follow-up under one narrow brand.
What failed first? The old frame
The earliest failure was not a CVR product. It was the way the market framed the patient. Visible veins were easy to classify as vanity; leg pain and swelling were easy to normalize. Conservative measures such as exercise, elevation, and compression stockings can ease symptoms, but they do not remove a diseased vein or stop a progressive condition. The patient could spend years treating the annoyance while the underlying reflux remained.
What changed Lakhanpal's mind was clinical observation. As a heart and vascular surgeon, he saw the suffering created by missed or untreated venous disease and concluded that a one-stop organization could meet the demand. That decision produced an unusually disciplined focus. CVR's public description is blunt: veins are its sole focus. In a sprawling healthcare system, specialization makes the referral easier to understand and gives the company enough procedure volume to build expertise.
The business model follows the medicine. Clinics bill for consultations, diagnostic imaging, and procedures, often through commercial insurance, Medicare, or Medicaid when coverage requirements are met. The exact patient cost depends on the plan, medical necessity, deductibles, and treatment sequence. CVR makes insurance navigation part of the experience rather than leaving the patient alone with a code and a phone tree.
The unglamorous machinery
The network has grown through clinic openings, physician recruitment, and partnerships with established practices. When a Cortec Group-led investor group acquired CVR in January 2016, the company managed 43 clinics in the Mid-Atlantic and Northeast. The price was not disclosed. Cortec described the deal as the first platform investment from its $1.1 billion sixth fund. A decade later, CVR's stated footprint is roughly three times larger.
The partnership pitch explains the engine. CVR centralizes marketing, billing, operational support, integration, technology, and tracked quality measures. Physicians are promised clinical control. That division of labor matters: the network can standardize the scaffolding without pretending a finance department should choose which vein to treat.
The 2026 addition of Inovia Vein Specialty Centers is the clearest recent example. The deal brought six clinics and eight specialists in Oregon and southwest Washington, giving CVR its first Pacific Northwest presence. The patient-facing promise was specific: same doctors, same care teams, same locations. CVR would add infrastructure and national reach behind the scenes. In July, Region Vein and Dr. Demetrios Karamichos joined in Northwest Indiana, pushing the footprint further.
That approach separates CVR from a loose directory of independent offices. It also separates it from a general hospital department, where vein care competes for attention and operating-room time. National competitors include USA Vein Clinics, United Vein & Vascular Centers, Metro Vein Centers, and Vein Clinics of America. Local vascular practices and hospital systems remain alternatives. CVR's differentiation is the combination of narrow focus, physical reach, a broad treatment menu, and a physician-led identity.
The supply problem hiding behind demand
More clinics require more people who understand the whole disease, not simply one device. CVR launched a 12-month Venous and Lymphatic Medicine Fellowship and welcomed its first fellow in 2017. The curriculum covers anatomy, ultrasound interpretation, patient selection, compression therapy, lymphatic disease, treatment planning, and long-term care. Its rationale is refreshingly practical: as minimally invasive tools became easier to use, physicians from many backgrounds could perform procedures without equivalent formal training in venous medicine.
Education now doubles as culture and capacity. CVR's careers materials emphasize collaboration, continuous learning, advancement, and physician leadership. Its annual VISION conference brings clinicians together for cases, research, and continuing medical education. VISION 2026 moved from Baltimore to Washington, DC, drew 20 percent more attendees than the prior year, and highlighted the company's early use of AI in education, diagnostic support, workflow, and patient engagement.
The part worth stealing
A specialty-service playbook
- Find a common problem that falls between cosmetic dismissal and hospital complexity.
- Own the diagnostic front door, not merely the final procedure.
- Offer several tools so clinicians can match the treatment to the patient.
- Centralize paperwork, marketing, technology, and measurement while keeping judgment local.
- Train the scarce talent you cannot reliably hire at scale.
The copyable insight is not “open vein clinics.” It is to look for a specialty where technology has moved faster than delivery. Then build the boring connective tissue that lets a good intervention reach more people: local access, clear positioning, insurance help, a training pipeline, and an integration process that patients barely notice.
The model has limits. It depends on procedure quality, reliable ultrasound, enough board-certified or well-trained clinicians, and payer coverage that supports medically necessary care. It is less attractive in sparsely populated markets that cannot feed a dedicated clinic, in categories where diagnosis requires hospital infrastructure, or when a rollup strips local physicians of autonomy. It also fails if growth outruns integration. A familiar sign on 130 doors is useful only when the care behind those doors remains consistent.
The condition is common, underdiagnosed, imageable, treatable in an office, and covered by a broad payer mix.
Specialist supply is thin, case volume is low, clinical autonomy disappears, or integration becomes visible to patients as friction.
There is a small irony in the name. Center for Vein Restoration restores no vein; it closes the bad one and lets the system reroute. The company has grown in much the same way. It did not rebuild American vascular care from scratch. It found underused routes - outpatient technology, independent specialists, local clinics, insurance coverage, and structured training - then connected them into a national circulation system.